

**Pediatric Psychopharmacology for Primary Care:
Evidence Supporting Short-Term Safety & Efficacy
of 8 Medications for Prescribing**

Medication	Primary Care Use	Supporting Studies	Age	Rate of Responders*	IE**
Methylphenidate: Short Acting	ADHD	Spencer et al. (1996): Review	N/A	N/A	N/A
		The MTA Cooperative Group (1999)	7-9.9 years	Not specified	No
		The PATS Team (2006)	3-5.5 years	A: 21%, P: 13%	No
Methylphenidate: Long Acting	ADHD	Greenhill et al. (2002)	6-16 years	A: 64%, P: 27%	No
		McGough & Wigal, et al. (2006): <i>Daytrana Patch</i>	6-12 years	A: 71%, P: 16%	No
		Findling et al. (2010): <i>Patch</i>	13-17 years	A: 66%, P: 21%	No
Amphetamine: Short Acting	ADHD	Spencer et al. (1996): Review	N/A	N/A	N/A
Amphetamine: Long Acting	ADHD	McGough & Biederman, et al. (2005): <i>Adderall XR</i>	6-12 years	Not specified	No
		Domniti & Madaan (2010): <i>LDX</i>	6-12 years	A: 70%, P: 18%	No
Guanfacine: Short Acting	ADHD	Scahill et al. (2001)	7-15 years	A: 53%, P: 0%	No
		Arnsten & Scahill, et al. (2007): Review	N/A	N/A	N/A
Guanfacine: Long Acting	ADHD	Biederman & Melmed, et al. (2008)	6-17 years	A: 50%, P: 26%	No
		Sallee & McGough, et al. (2009)	6-17 years	A: 56%, P: 30%	No
Atomoxetine	ADHD	Michelson & Faries, et al. (2001)	8-18 years	Not specified	No
Fluoxetine	Anxiety	Birmaher & Axelson, et al. (2003)	7-17 years	A: 61%, P: 35%	No
	MDD	Emslie & Rush, et al. (1997)	7-17 years	A: 56%, P: 33%	No
		Emslie & Heiligenstein, et al. (2002)	8-18 years	A: 65%, P: 53%	No
		TADS Team (2004)	12-17 years	A: 61%, P: 35%	Yes
	OCD	Riddle & Scahill, et al. (1992)	8-15 years	A: 33%, P: 12%	No
		Geller & Hoog, et al. (2001)	7-17 years	A: 49%, P: 25%	No
		Liebowitz & Turner, et al. (2002)	6-18 years	A: 57%, P: 27%	Yes
Sertaline	Anxiety	Walkup et al. (2008)	7-17 years	A: 55%, P: 24%	Yes
	MDD	Wagner & Ambrosini, et al. (2003)	6-17 years	A: 36%, P: 24%	No
	OCD	March & Biederman, et al. (1998)	13-17 years	A: 42%, P: 26%	No
		POTS Team (2004)	7-17 years	A: 21%, P: 4%	Yes
Escitalopram	MDD	Wagner et al. (2006)	6-17 years	A: 63%, P: 52%	No
		Emslie & Ventura, et al. (2009)	12-17 years	A: 62%, P: 52%	No

*A=Active drug recipients; P=Placebo recipients

**IE=Independent Evaluator – Use of such evaluators to rate symptom severity may help reduce bias, since these individuals are blinded to patient side effects that could reveal their treatment assignment

Compiled by Mark A. Riddle, MD, and Susan dosReis, PhD, Center for Mental Health Services in Pediatric Primary Care, Johns Hopkins School of Public Health. Updated July 2011.